Results 191 to 200 of about 38,268 (270)

Systematic review and meta‐analysis of the efficacy and safety of [177Lu]Lu‐edotreotide ([177Lu]Lu‐DOTATOC) for the treatment of neuroendocrine tumors

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract [177Lu]Lu‐edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta‐analysis describes the efficacy and safety of [177Lu]Lu‐edotreotide in patients with NETs.
Richard P. Baum, Julia G. Fricke, Tristan Ruhwedel, Holger Amthauer, Erika Patricia Azorin‐Vega, Dieter Hörsch, Riccardo Laudicella, Vikalp Maheshwari, Martin A. Walter, Berna Degirmenci Polack, Simon F. Spiegl, Guillaume P. Nicolas   +11 more
wiley   +1 more source

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238

, 2000
Naoual Benali, Pierre Cordelier, Denis Calise, Philippe Pagès, Philippe Rochaix, Attila Nagy, Jean‐Pierre Estève, Parviz M. Pour, Andrew V. Schally, Nicole Vaysse, Christiane Susini, Louis Buscail   +11 more
openalex   +2 more sources

Supplementary Figure 5 from ¹⁷⁷Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

, 2023
Shilpa Thakur, Brianna Daley, Corina Millo, Craig Cochran, Orit Jacobson, Huiyan Lu, Zhantong Wang, Dale O. Kiesewetter, Xiaohong Chen, Vasyl Vasko, Joanna Kłubo-Gwieździńska   +10 more
openalex   +1 more source

Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Somatostatin analogs (SSAs) are an established first‐line therapy in intestinal and pancreatic neuroendocrine tumors (NETs). Based on Phase III studies, their use is recommended in NET with a Ki‐67 index of up to 10%. The effect of first‐line SSA therapy on differentiated NET with a Ki‐67 index ≥10% is poorly understood.
Johanna Braegelmann, Annie Mathew, Boerge Schmidt, Hamza Kalisch, Wolfgang P. Fendler, Dagmar Führer‐Sakel, Harald Lahner   +6 more
wiley   +1 more source

Supplementary Figure 1 from ¹⁷⁷Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

, 2023
Shilpa Thakur, Brianna Daley, Corina Millo, Craig Cochran, Orit Jacobson, Huiyan Lu, Zhantong Wang, Dale O. Kiesewetter, Xiaohong Chen, Vasyl Vasko, Joanna Kłubo-Gwieździńska   +10 more
openalex   +1 more source

Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Bone metastases (BMs) were reported in <15% of cases of neuroendocrine neoplasms (NENs). Their clinical behavior is various and clinical management is still undefined. This study aimed to describe the clinical practical management and survival outcome of neuroendocrine neoplasm patients with BMs.
Nicola Fazio, Patrick Maisonneuve, Anna Maria Frezza, Nicoletta Ranallo, Toni Ibrahim, Anna La Salvia, Maria Pia Brizzi, Chiara De Divitiis, Salvatore Tafuto, Sara Pusceddu, Riccardo Marconcini, Mauro Cives, Cristina Ferrari, Davide Campana, Delia De Lisi, Daniele Santini, Antongiulio Faggiano, Roberta Modica, Sara Massironi, Antonio Bianchi, Francesco Panzuto, Lorenzo Antonuzzo, Elisa Pellegrini, Vito Amoroso, Ivana Puliafito, Elettra Merola, Nicola Silvestris, Chiara Maria Grana, Francesca Spada   +28 more
wiley   +1 more source

The gatekeepers of growth: The neural roles and regulation of growth hormone‐releasing hormone neurons

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract The neuroendocrine control of growth is mediated by the hypothalamic–pituitary–somatic (HPS) axis. This involves the hypothalamic release of growth hormone‐releasing hormone (GHRH), which stimulates the pituitary secretion of growth hormone (GH).
Bradley B. Jamieson
wiley   +1 more source

11C‐Hydroxyephedrine PET/CT for preoperative surgical planning in large pheochromocytoma and paraganglioma

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Early detection of metastases and timely surgical intervention play a crucial role in the management of neuroendocrine tumors. In large‐sized pheochromocytomas and sympathetic paragangliomas (PPGL), functional imaging with positron emission tomography (PET) is recommended, as it improves the detection of metastases, which may go undetected on ...
Achyut Ram Vyakaranam, Olov Norlén, Alina Akural, Joakim Crona, Matilda Annebäck, Branislav Klimàcek, Peter Stålberg, Anders Sundin, Tobias Åkerström   +8 more
wiley   +1 more source

Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes. [PDF]

Front Pharmacol
D'Souza NC, Aiken JA, Hoffman EG, Atherley SC, Champsi S, Aleali N, Shakeri D, El-Zahed M, Akbarian N, Nejad-Mansouri M, Bavani PZ, Liggins RL, Chan O, Riddell MC.   +13 more
europepmc   +1 more source

Incidence and Characteristics of Hospital‐Acquired Pressure Injuries in Acute Palliative Care Patients: A Four‐Year Analysis

Journal of Clinical Nursing, Volume 35, Issue 1, Page 255-267, January 2026.
ABSTRACT Aim To describe the cumulative incidence and characteristics of hospital‐acquired pressure injury in acute palliative patients. Design Secondary data analysis of hospital‐acquired pressure injuries during 2019–2022. Methods The setting was a palliative care unit at a tertiary hospital in Queensland, Australia, including adult (≥ 18 years ...
Saroeun Ven, Michael Steele, Adam Burston, Paul Fulbrook, Josephine Lovegrove, Sandra Miles, Susan Prince   +6 more
wiley   +1 more source